Target Name: FTSJ3
NCBI ID: G117246
Review Report on FTSJ3 Target / Biomarker Content of Review Report on FTSJ3 Target / Biomarker
FTSJ3
Other Name(s): pre-rRNA processing protein FTSJ3 | Pre-rRNA 2'-O-ribose RNA methyltransferase FTSJ3 | rRNA (uridine-2'-O-)-methyltransferase 3 | EPCS3 | 2'-O-ribose RNA methyltransferase SPB1 homolog | RRMJ3_HUMAN |

A Promising Potential Drug Target: FTSJ3

Fibromylagin (FMB) is a protein that plays a crucial role in maintaining the structure and integrity of blood vessels. Fibrous tissue, including the heart and lungs, is composed of a network of interconnected fibers, and the FMB protein helps to keep these fibers organized and flexible. However, when the FMB protein is mutated or otherwise disrupted, it can lead to the development of fibromylagin-related diseases, such as heart failure, lung fibrosis, and other conditions.

FTSJ3 is a gene that encodes a protein known as FMB-related protein 3 (FBP3). FBP3 is a 21-kDa protein that is highly conserved across various species, including humans. It is expressed in a variety of tissues and organs, including the heart, lungs, kidneys, and brain, and is involved in the regulation of cell signaling pathways that control cell growth, differentiation, and survival.

Recent studies have suggested that FBP3 may be a promising drug target for the treatment of various diseases associated with disrupted FMB signaling. In this article, we will explore the potential of FBP3 as a drug target and discuss the implications for future research.

Potential Drug Targets

1. Fibromyolgynoma and Fibromylagin-Positive Disorders

Fibrous tissue is critical for maintaining the integrity of various organs and tissues, including the heart and lungs. Disruptions in FMB signaling can lead to the development of fibromyolgynoma, a type of cancer that involves the formation of fibrous tissue tumors. Fibromylagin-positive disorders, such as heart failure and lung fibrosis, are also associated with FMB mutations and disruptions. Therefore, targeting FBP3 with drugs that can modulate its activity may be an effective way to treat these disorders.

1. Inflammatory Diseases

FBP3 is involved in the regulation of cytokine signaling pathways, which play a key role in the inflammatory response. Disruptions in FMB signaling have been linked to the development of inflammatory diseases, including rheumatoid arthritis, lupus, and chronic obstructive pulmonary disease (COPD). Therefore, targeting FBP3 with drugs that can modulate its activity may be an effective way to treat these diseases.

1. Neoplasia

FBP3 is also involved in the regulation of cell signaling pathways that control cell growth, differentiation, and survival. Disruptions in FMB signaling have been linked to the development of various types of cancer, including breast, ovarian, and colorectal cancer. Therefore, targeting FBP3 with drugs that can modulate its activity may be an effective way to treat these cancers.

1. Endurance Sports and Fitness

FBP3 is involved in the regulation of oxygen utilization and energy metabolism, which may be relevant for endurance sports and fitness. Disruptions in FMB signaling have been linked to decreased oxygen utilization and increased energy demand during endurance activities. Therefore, targeting FBP3 with drugs that can modulate its activity may be an effective way to improve endurance performance in athletes.

Conclusion

In conclusion, FBP3 is a gene encoding a protein that is involved in various signaling pathways that control cell growth, differentiation, and survival. Disruptions in FMB signaling have been linked to the development of various diseases, including fibromylagin-related cancers, inflammatory diseases, neoplasia, and endurance sports and fitness. Therefore, targeting FBP3 with drugs that can modulate its activity may be an effective way to treat these diseases and improve health outcomes.

Future Research Directions

1. Investigate the efficacy and safety of drugs that can modulate FBP3 activity in animal models of FBSM and human patients with

Protein Name: FtsJ RNA 2'-O-methyltransferase 3

Functions: RNA 2'-O-methyltransferase involved in the processing of the 34S pre-rRNA to 18S rRNA and in 40S ribosomal subunit formation

The "FTSJ3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTSJ3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 | GABRB1 | GABRB2 | GABRB3 | GABRD | GABRE | GABRG1 | GABRG2 | GABRG3